Day procedures and higher-end outpatient care were flagged as key drivers, with the study also pointing to panel providers and group plans as potential cost moderators.
The Australian regulator has sought views from market participants on potential impact of Zurich-ClearView, ahead of the 4 June 2026 decision deadline.